MedPath

GRANULES INDIA

🇮🇳India
Ownership
-
Employees
-
Market Cap
$2B
Website

USFDA Issues Warning to Granules India Over Critical Manufacturing Violations at Telangana Facility

The US Food and Drug Administration has issued a warning letter to Granules India citing serious contamination issues and inadequate maintenance at its Telangana formulations plant following an inspection conducted in August-September 2024.

FDA Issues Warning Letter to Granules India for GMP Violations at Telangana Facility

The U.S. Food and Drug Administration has issued a warning letter to Granules India citing significant Good Manufacturing Practice (GMP) violations at its Telangana manufacturing plant.

© Copyright 2025. All Rights Reserved by MedPath